{
    "nct_id": "NCT03180528",
    "official_title": "A Phase 2 Open-Label, Single-Arm Trial of the Efficacy of Topical Remetinostat on Basal Cell Carcinoma in Patients",
    "inclusion_criteria": "* Must have at least one BCC lesion > 1 cm (BCC > 5 mm) in non-cosmetically sensitive site(s)\n* Must be willing to apply the topical remetinostat 3 times daily for 6 weeks\n* For women of child bearing potential, a negative urine pregnancy test\n* Women of child bearing potential are expected to use an effective method of birth control while participating in the study and for 1 month after applying the last dose\n* For male subjects with female partners of childbearing potential, agreement to use adequate contraception while participating in the study and for 1 month after applying the last dose\n* Has signed and dated the current Institutional Review Board (IRB) approved informed consent document\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Taking any medication known to interact with histone deacetylase (HDAC) inhibitors, such as valproate or anticoagulants\n* Taking any medication known to affect hedgehog (HH) signaling pathway such as itraconazole\n* Within the past 6 months, has used topical or systemic therapies that might interfere with the evaluation of the study medication during the study; specifically, these include the topical use to the study tumors of:\n\n  * Glucocorticoids\n  * Retinoids either systemically or topically (eg, etretinate, isotretinoin, tazarotene, tretinoin, adapalene)\n  * Alpha hydroxy acids (eg, glycolic acid, lactic acid) to > 5% of the skin\n  * 5 fluorouracil or imiquimod and/or\n  * Itraconazole\n* Has received treatment with systemic chemotherapy or agents known to be inhibitors of HH signaling, within 60 days to starting study medication\n* Currently receiving systemic medications that could affect BCC tumors (eg, oral retinoids) or might interact with remetinostat\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, recurrent seizure history or psychiatric illness/social situations that would limit compliance with study requirements\n* Moderate to severe immunosuppression due to disease or medication\n* Known or previous hypersensitivity to histone deacetylase inhibitor (HDACi)\n* History of congestive heart failure; cardiac arrhythmias; or other findings of ventricular dysfunction\n* History of current evidence of malabsorption or liver disease\n* Pregnancy or breast feeding",
    "miscellaneous_criteria": ""
}